Prevention and treatment of venous thromboembolism related to coronavirus Covid-19.


Coronavirus Covid 19. Very interesting article which highlights the cause of the mortality of Coronavirus infection: venous thromboembolism.

It is an article published by a team of doctors from the University of Lanzhou, China.

Coronavirus Covid 19. Article extrapolated from Pubmed

Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019. [Epub ahead of print]

Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.

(Zhai Z#1,2,3Li C#4Chen Y#5Gerotziafas G6Zhang Z7Wan J1,2,3Liu P8Elalamy I6,9Wang C1,2,3,10Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group, Pulmonary Embolism Pulmonary Vascular Diseases Group of the Chinese Thoracic Society, Pulmonary Embolism Pulmonary Vascular Disease Working Committee of Chinese Association of Chest Physicians, National Cooperation Group on Prevention Treatment of Pulmonary Embolism Pulmonary Vascular Disease, National Program Office for Prevention Treatment of Pulmonary Embolism Deep Vein Thrombosis, China Grade Center, Evidence-based Medicine Center of School of Basic Medical Sciences of Lanzhou University).

Coronavirus Covid 19. Author information


Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. 

Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. 

This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.

Georg Thieme Verlag KG Stuttgart ยท New York.PMID: 32316065  DOI: 10.1055/s-0040-1710019

So from what we understand it is that this pathology triggers a great inflammation of the endothelial tissue of the vessels. Inflammation is the first phase, followed by the second phase of hypercoagulability with thrombi formation.

We will therefore try to suggest, in the next articles, which foods, supplements, phytotherapy and homeopathic remedies we can use to lower our basic inflammatory level.

Articolo precedenteEndometriosis. A psychological-archetypal reading
Articolo successivoCoronavirus and prevention


Per favore inserisci il tuo commento!
Per favore inserisci il tuo nome qui